Bader, Justin C.
Abdul Razak, Albiruni R.
Shacham, Sharon
Xu, Hongmei http://orcid.org/0000-0002-8650-8694
Article History
Accepted: 13 March 2021
First Online: 29 April 2021
Declarations
:
: No external funds were used in the preparation of this manuscript.
: Justin C. Bader and Hongmei Xu are full-time employees of Karyopharm Therapeutics and own stock/stock options in the company. Sharon Shacham is Chief Scientific Officer of Karyopharm Therapeutics and owns stock/stock options in the company. Albiruni R. Abdul Razak is full-time employee of Princess Margaret Cancer Centre, Toronto, and has received research funding from Karyopharm Therapeutics.
: The Institutional Review Boards or Independent Ethics Committees of all investigational sites approved all Clinical Studies and all studies were performed in accordance with the Declaration of Helsinki and Good Clinical Practice.
: All study participants provided consent form for study participation.
: I have signed the license agreement for publication.
: Not applicable.
: Not applicable.
: All authors have contributed to the preparation and review of this manuscript.